Weekly Recap: CRB-701 42.9% ORR in OPSCC and $118M cash position

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) reported promising ASCO and CANYON-1 data—CRB-701 at 3.6 mg/kg showed 42.9% ORR in OPSCC with 6.3-month median DOR and manageable safety, while 60 mg in Phase 1b yielded ~5% placebo-adjusted weight loss and good tolerability, backed by ~$118M cash.

Previous Week Recap

• CRBP ASCO Data: 42.9% ORR: Corbus Pharmaceuticals (CRBP) reported ASCO data: CRB-701 at 3.6 mg/kg showed 42.9% confirmed ORR in OPSCC, median duration of response 6.3 months, and a manageable safety profile.
  • 
  TradingView
• CRBP Cash Of $118M: Corbus Pharmaceuticals (CRBP) held about $118M cash and investments as of June 30, 2026. Shares outstanding: ~18.7M, ~22.4M fully diluted.
  • 
  TradingView
• CANYON-1 60mg Weight Loss: Corbus Pharmaceuticals (CRBP) reported CANYON-1 Phase 1b: ~5% placebo-adjusted weight loss at 12 weeks with 60 mg, favorable GI and psychiatric tolerability, Phase 2 monotherapy slated H1 2027.
  • 
  TradingView